IP Library Granted Patent US 12698333
Granted Patent B2
US 12698333 · App. 17/629,681 · Granted Aug 4, 2026

CAR-CD123 vector and uses thereof

Inventors: Concetta Quintarelli (Rome, IT); Biagio De Angelis (Rome, IT); Franco Locatelli (Rome, IT)
Assignee: OSPEDALE PEDIATRICO BAMBINO GESU′
C07K16/2866A61K40/11A61K40/15A61K40/31A61K40/4211A61K40/4217A61P35/02C07K14/7051C12N5/0636C12N5/0646A61K2239/29A61K2239/31A61K2239/38A61K2239/48
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12698333
App. No.
17/629,681
Granted
Aug 4, 2026
Kind
B2
Abstract

The present invention relates to a chimeric antigen receptor (CAR) molecule containing, from the N-terminus to the C-terminus: a) an extracellular domain and transmembrane domain of human CD19, b) an antigen binding domain, c) a spacer domain, d) a transmembrane domain, and e) a cytoplasmatic domain, preferably wherein the CAR is a CD123 specific CAR (CD123 CAR) and the antigen binding domain includes a VL and/or VH from a monoclonal anti-CD123 antibody, more preferably the antigen binding domain includes a single chain variable fragment (scFv) that specifically binds to CD123.

Claims (7)

1 . A chimeric antigen receptor (CAR) molecule comprising, the sequence of SEQ ID NO: 12.

2 . The CAR molecule according to claim 1 , that consists of the sequence of SEQ ID NO: 12.

3 . An isolated nucleic acid molecule encoding the chimeric antigen receptor molecule according to claim 1 , wherein said isolated nucleic acid molecule is operatively linked to expression control sequences.

4 . A vector comprising the isolated nucleic acid molecule according to claim 3 .

5 . An isolated engineered immune cell, comprising the vector according to claim 4 .

6 . A composition comprising the isolated nucleic acid molecule according to claim 3 , and a pharmaceutically acceptable excipient and/or adjuvant.

7 . A composition comprising a transduced cell comprising the CAR molecule of claim 1 .